Small Pharma issues a corporate update, reporting R&D and IP progress, with ~CAD$40 million in cash as of February 28, 2022.
Pharmather announces a new development agreement with CCBIO to create a proprietary wearable ketamine delivery solution for mental health.
Compass Pathways announces the release of the largest randomized, controlled, double-blind study ever completed on psilocybin-assisted therapy.
MindMed announces the appointment of Schond L. Greenway as its new CFO, bringing a wealth of experience in banking and corporate finance.
MindMed announces positive safety and tolerability results from its Phase 1 clinical trial of MM-110 (18-MC) as a treatment for opioid withdrawal.
Optimi Health announces that UK MP, Cristin Blunt will be appearing as a guest speaker at the grand opening ceremony for its Princeton, B.C. cultivation facility.
Awakn Life Sciences announce promising results from the first study of ketamine-assisted therapy for behavioral addictions, and will be initiating a larger follow-up study.
Mydecine Innovations Group announces the issuance of 3,478,260 units at a unit price of CAD$1.15, for gross proceeds of up to CAD$4 million.
Albert Labs announces the receipt of its Dealer's License from Health Canada, allowing possession/sale/delivery of psilocybin and other controlled substances.
MindMed announces an at-the-market financing with a prospectus authorizing share sales of up to $100,000,000. Not open to Canadian investors.